CYPHERPUNK TECHNOLOGIES INC. Finance Lease, Right-of-Use Asset, Amortization
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Finance Lease, Right-of-Use Asset, Amortization of $177.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2019-05-15
- CYPHERPUNK TECHNOLOGIES INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-03-31 was $177.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month |
|---|---|
| 2019-03-31 | $177.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |